Compare BOSC & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOSC | GRML |
|---|---|---|
| Founded | 1990 | N/A |
| Country | Israel | United States |
| Employees | N/A | 5 |
| Industry | Computer Communications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 34.9M |
| IPO Year | 2002 | 2022 |
| Metric | BOSC | GRML |
|---|---|---|
| Price | $4.25 | $0.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 30.3K | ★ 3.7M |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $0.16 |
| 52 Week High | $6.72 | $0.55 |
| Indicator | BOSC | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 34.13 |
| Support Level | $4.10 | N/A |
| Resistance Level | $4.93 | $0.34 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 11.43 | 13.49 |
BOS Better Online Solutions Ltd is a provider of comprehensive solutions to enterprises, comprised of services, equipment, and custom-made automatic machines. The company manages its business in three reportable divisions: the Supply Chain Solutions Division, the RFID Division, and the Intelligent Robotics Division. The majority of revenue derives from Supply Chain Solutions, which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their component-supply needs. Its geographic areas are Israel, East Asia, India, America, Europe, and the rest of the world. Geographically company derives the majority of its revenue from Israel.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.